Novel Targeted Therapies for Esophagogastric Cancer.

Item

http://www.wikidata.org/entity/Q39171565

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Novel Targeted Therapies for Esophagogastric Cancer.

@en

Novel Targeted Therapies for Esophagogastric Cancer.

@nl

type

Item

label

Novel Targeted Therapies for Esophagogastric Cancer.

@en

Novel Targeted Therapies for Esophagogastric Cancer.

@nl

prefLabel

Novel Targeted Therapies for Esophagogastric Cancer.

@en

Novel Targeted Therapies for Esophagogastric Cancer.

@nl

P1476

Novel Targeted Therapies for Esophagogastric Cancer.

@en

P2093

Daniel V T Catenacci

http://www.w3.org/2001/XMLSchema#string

Steven B Maron

http://www.w3.org/2001/XMLSchema#string

P2860

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity

Signaling cross-talk in the resistance to HER family receptor targeted therapy

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.

Global cancer statistics, 2012

Cancer statistics, 2015

P304

293-312

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.SOC.2016.10.002

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28279470

http://www.w3.org/2001/XMLSchema#string

P932

5347475

http://www.w3.org/2001/XMLSchema#string